Top Suppliers:I want be here

850649-61-5

850649-61-5 structure
850649-61-5 structure
  • Name: Alogliptin
  • Chemical Name: alogliptin
  • CAS Number: 850649-61-5
  • Molecular Formula: C18H21N5O2
  • Molecular Weight: 339.392
  • Catalog: Biochemical Inhibitor Proteases DPP-4 inhibitor
  • Create Date: 2018-07-18 07:06:09
  • Modify Date: 2026-07-02 08:43:43
  • Alogliptin(SYR-322) is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.IC50 value: <10 nMTarget: DPP4Alogliptin is an orally administered, anti-diabetic drug in the DPP-4 inhibitor class. A randomized clinical trial reporting in 2011 aimed to determine the efficacy and safety of alogliptin versus placebo and voglibose among newly diagnosed Type 2 diabetes patients in Japan. The main outcome indicated that alogliptin was statistically superior to both comparitors. A randomized clinical trial reporting in 2012 aimed to demonstrate that alogliptin was "non-inferior" to a "very low fat/calorie traditional Japanese diet" among newly diagnosed Type 2 diabetes patients in Japan. The outcome indicated that both the drug and dietary treatments comparably impacted indicators of the diabetic condition, such as HbA1c levels and glycemic efficacy. The drug treatment had its impact without changing body mass index (BMI), but the dietary treatment was accompanied by a significant reduction in the BMI…

Name alogliptin
Synonyms Alogliptin Base
ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA)
Trelagllptin Impurity 2
ALOGLIPTIN(ALOGLIPTINE
(R)-2-[6-(3-amino-piperidin-1-yl)-3-Methyl-2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)Methyl]-benzonitrile
Benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-Methyl-2,4-dioxo-1(2H)-pyriMidinyl]Methyl]
Alogliptin(free base)
Alogliptin 13C6
2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile
alogliptina
ALOGLIPTINA
Alogliptin(850-5)
Axagliptin hydrate
Alogliptin effective and selective DPP-4 inhibitor
ALOGLIPTINE
Trelagliptin Impurity T
Unii-jhc049lo86
UNII-JHC049LO86
Alogliptin Intermediate
2-({6-[(3R)-3-Amino-1-piperidinyl]-3-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl}methyl)benzonitrile
ALOGLIPTIN(ALOGLIPTINE,ALOGLIPTINA)
Alogliptin Benzoate API
Alogliptin (SYR-322)
Trelagliptin-11
AlogliptinQ: What is Alogliptin Q: What is the CAS Number of Alogliptin Q: What is the storage condition of Alogliptin Q: What e the applications of Alogliptin
Troxagliptin impurities141
Trajenta
Troxagliptin impuritiesT
Agelieting
2-[[6-[(3R)-3-Amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile
ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA)###850-5
Trelagliptin Impurity 2(Alogliptin)
ogL
2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile
Alogliptin, 10 mM in DMSO
Alogliptin 2-[[6-[(3R)-3-Amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile
(R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitri
Description Alogliptin(SYR-322) is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.IC50 value: <10 nMTarget: DPP4Alogliptin is an orally administered, anti-diabetic drug in the DPP-4 inhibitor class. A randomized clinical trial reporting in 2011 aimed to determine the efficacy and safety of alogliptin versus placebo and voglibose among newly diagnosed Type 2 diabetes patients in Japan. The main outcome indicated that alogliptin was statistically superior to both comparitors. A randomized clinical trial reporting in 2012 aimed to demonstrate that alogliptin was "non-inferior" to a "very low fat/calorie traditional Japanese diet" among newly diagnosed Type 2 diabetes patients in Japan. The outcome indicated that both the drug and dietary treatments comparably impacted indicators of the diabetic condition, such as HbA1c levels and glycemic efficacy. The drug treatment had its impact without changing body mass index (BMI), but the dietary treatment was accompanied by a significant reduction in the BMI…
Related Catalog
References

[1]. Feng J, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007 May 17;50(10):2297-300.

[2]. Ta NN, et al. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis. 2010 Dec;213(2):429-35.

[3]. Asakawa T, et al. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. Life Sci. 2009 Jul 17;85(3-4):122-6.

[4]. Moritoh Y, et al. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. Eur J Pharmacol. 2009 Jan 14;602(2-3):448-54.

[5]. Kajiwara A, et al. Risk Factors for Adverse Symptoms During Dipeptidyl Peptidase-IV Inhibitor Therapy: A Questionnaire-Based Study Carried Out by the Japan Pharmaceutical Association Drug Event Monitoring Project in Kumamoto Prefecture. Drug Saf. 2013 Oct

Density 1.3±0.1 g/cm3
Boiling Point 519.2±60.0 °C at 760 mmHg
Molecular Formula C18H21N5O2
Molecular Weight 339.392
Flash Point 267.8±32.9 °C
Exact Mass 339.169525
PSA 97.05000
LogP 1.84
Vapour Pressure 0.0±1.4 mmHg at 25°C
Index of Refraction 1.660
Hazard Codes Xi
Safety Phrases 24/25
RIDADR 3077
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.